The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

Thu, 26th Aug 2021 12:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Caerus Mineral Resources PLC - copper and gold explorer with licenses in Cyprus - Alongside copper-gold exploration and development company Bezant Resources PLC, Caerus notes the Troulli project in Cyprus has been selected as the first project for a joint-venture. "The joint review, which will also have input from Jubilee Metals Group PLC, will cover all waste recycling and hard rock VMS projects within the Caerus portfolio with an emphasis on Troulli as the first joint venture project between Caerus and Bezant," Caerus explains. Says diamond drilling and resource estimate programme to be agreed at project.

----------

TomCo Energy PLC - oil project development in US focused on using new technology to unlock unconventional hydrocarbon resources - Buys Valkor LLC's 50% interest in the Greenfield Energy LLC joint-venture. TomCo now owns all of Greenfield. Will fund the acquisition through a deferred issue of 592.8 million shares, currently 29% of the company's capital.

----------

Power Metal Resources PLC - metal exploration and development in Africa - Says total of 19 holes completed at first phase of diamond drilling exploration programme at Silver Peak project in Canada. "All cores are being logged, catalogued and split by independent geological consultants prior to being sent to ALS Canada Ltd in Vancouver, British Columbia, for accredited laboratory assay analysis," Power Metal adds. Establishes new vehicle named Silver Peak Resources Ltd in anticipation of public listing of project, or to allow for a third party acquisition. At Tati in Botswana, crews have been mobilised for phase 2 work programme on the gold and nickel greenstone belt.

----------

Aura Energy Ltd - Australia-based minerals company - Completes gravity survey at Tasiast South tenements in Mauritania. "The gravity data allows better definition of geology, the identification of structures likely to be of relevance to gold deposition and the possibility of direct detection of sulphide mineralisation on the nickel/cobalt targets," Aura says.

----------

Westmount Energy Ltd - invests in companies which operate in oil & gas related industries - Notes beginning of drilling at Sapote-1, located in Canje block in offshore Guyana. Westmount holds a 7.2% interest in Canje, which is operated by Exxon Mobil Corp. Exxon's Esso Exploration & Production Guyana Ltd has a 35% stake, TotalEnergies SE unit TotalEnergies E&P Guyana BV also holds 35%.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Secures USD24 million supply and distribution pact with AMC Holdings Inc for its phytomedicine products. The deal lasts three years. "This is MGC Pharma's first USA supply agreement dedicated to taking MGC's pharmaceutical phytocannabinoid products into the world's largest healthcare market," company adds. For the first year, AMC will pay MGC USD750,000 and a letter of credit for a further USD2.3 million.

----------

Scancell Holdings PLC - Oxford, England-based immunotherapies for treatment of cancer and infectious disease - Says UK's Medicines & Healthcare Products Regulatory Authority approves plans to kick off first-in-human trial of Modi-1 vaccine which targets cancer cells. "The company expects to enrol patients into the study in the second half of 2021, following ethics committee sign-off. Initial safety and tolerability data from the initial open label portion of the trial could be available from the first half of 2022," Scancell says.

----------

Eden Research PLC - Cirencester-based agricultural chemicals producer - Says Mevalone biofungicide receives green light for use on new crops in Portugal. The product is used to treat Botrytis cinerea, a fungal pathogen. "This latest label extension adds strawberries, raspberries, blueberries, cranberries, kiwi, aubergines and peppers to the label, with product applications being permitted close to the point of harvest," Eden explains.

----------

Bidstack Group PLC - London-based in-game advertising platform - Partners with Motionlab Interactive, the makers of mobile game PDC Darts Match. PDC is the Professional Darts Corp, a darts governing body. "The new game expands Bidstack's stadium vertical and increases the number of sports covered to five different categories (football, tennis, cricket, jiu-jitsu and darts)," Bidstack explains.

----------

D4t4 Solutions PLC - Surrey-based data management company - Says continuing to trade in line with board expectation. "The business is delivering against its key KPIs and is well positioned in its core markets," D4t4 says. Says rolllout of Celebrus Fraud Data platform progresses. Company adds: "D4t4 has also commenced a marketing and PR campaign, particularly focused on raising the profile of Celebrus products in the US market."

----------

Braemar Shipping Services PLC - London-based shipbroker - "Pleased" by performance in first five months of financial year ended February. Braemar says: "Trading has been good across all three of the group's divisions and the breadth of the group's business model, the diversity of the broking operation and the markets in which the group now operates, have insulated the business well from any ongoing pandemic weakness."

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.